BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• Press Releases

  Stylus Medicine Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting

  May 13, 2025

   · 

  3 min read
• Press Releases

  Sail Biomedicines Presents Preclinical Data on In Vivo eRNA™ CAR-T Candidate for Autoimmune Diseases at ASGCT 2025

  May 13, 2025

   · 

  4 min read
• Press Releases

  AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025

  May 13, 2025

   · 

  19 min read
• Press Releases

  Sonoma Biotherapeutics Appoints Rajesh Krishnan, Ph.D., as Chief Technical Officer

  May 13, 2025

   · 

  2 min read
• 

  Funding

  Azafaros Raises $150M To Target Rare Neuro-Metabolic Diseases

  Azafaros will use the Series B haul to push lead asset nizubaglustat into late-stage studies for Niemann-Pick disease Type C and GM1/GM2 gangliosidoses later this year.

  May 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Cytokinetics Announces Positive Topline Results From MAPLE-HCM

  May 13, 2025

   · 

  8 min read
• Press Releases

  Affinia Therapeutics Presents New Data on its Lead AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th American Society of Gene & Cell Therapy 2025 Annual Meeting

  May 13, 2025

   · 

  7 min read
• 

  Drug pricing

  CMS Prepares for Third Cycle of Drug Negotiations as Trump Intensifies Push To Lower Prices

  The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in 2028.

  May 13, 2025

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Pharmacy benefit managers

  Trump’s Most Favored Nation Policy Sparks PBM Selloff

  The Most Favored Nation directive would allow drugmakers to directly sell their products to patients at a lower cost, cutting out what President Donald Trump called “the middlemen.”

  May 13, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Reviva to Participate in the A.G.P. Healthcare Company Showcase

  May 13, 2025

   · 

  1 min read